Research Analysts Offer Predictions for Amedisys Q1 Earnings

Amedisys, Inc. (NASDAQ:AMED) – Stock analysts at William Blair decreased their Q1 2025 earnings per share estimates for shares of Amedisys in a research note issued on Thursday, February 27th. William Blair analyst M. Larew now forecasts that the health services provider will earn $0.98 per share for the quarter, down from their prior estimate of $1.01. The consensus estimate for Amedisys’ current full-year earnings is $4.40 per share. William Blair also issued estimates for Amedisys’ Q2 2025 earnings at $1.33 EPS, Q3 2025 earnings at $1.05 EPS, Q4 2025 earnings at $1.08 EPS and FY2025 earnings at $4.45 EPS.

Separately, Stephens reiterated an “equal weight” rating and set a $101.00 price objective on shares of Amedisys in a research report on Wednesday, February 12th. Five research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $100.75.

Amedisys Stock Up 0.3 %

AMED stock opened at $92.00 on Friday. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.19 and a quick ratio of 1.19. The stock has a market capitalization of $3.01 billion, a price-to-earnings ratio of 36.51, a PEG ratio of 1.78 and a beta of 0.73. The business’s fifty day moving average price is $91.41 and its two-hundred day moving average price is $93.21. Amedisys has a fifty-two week low of $82.15 and a fifty-two week high of $98.95.

Amedisys (NASDAQ:AMED) last posted its quarterly earnings data on Wednesday, February 26th. The health services provider reported $0.96 earnings per share for the quarter, missing the consensus estimate of $1.05 by ($0.09). The firm had revenue of $598.05 million for the quarter, compared to the consensus estimate of $602.38 million. Amedisys had a return on equity of 12.20% and a net margin of 3.57%.

Institutional Trading of Amedisys

Several large investors have recently modified their holdings of AMED. Blue Trust Inc. grew its holdings in shares of Amedisys by 55.1% during the 4th quarter. Blue Trust Inc. now owns 349 shares of the health services provider’s stock worth $34,000 after purchasing an additional 124 shares in the last quarter. HBW Advisory Services LLC acquired a new stake in shares of Amedisys during the 4th quarter worth $38,000. Versant Capital Management Inc grew its holdings in shares of Amedisys by 68.5% during the 4th quarter. Versant Capital Management Inc now owns 450 shares of the health services provider’s stock worth $41,000 after purchasing an additional 183 shares in the last quarter. Johnson Financial Group Inc. acquired a new stake in Amedisys in the fourth quarter valued at about $55,000. Finally, KBC Group NV acquired a new stake in Amedisys in the third quarter valued at about $63,000. 94.36% of the stock is owned by institutional investors and hedge funds.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.